A detailed history of Pacer Advisors, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 4,278,563 shares of ALKS stock, worth $100 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
4,278,563
Previous 770 555557.53%
Holding current value
$100 Million
Previous $21,000 551423.81%
% of portfolio
0.3%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$26.4 - $32.56 $113 Million - $139 Million
4,277,793 Added 555557.5%
4,278,563 $116 Million
Q4 2023

Jan 16, 2024

BUY
$23.37 - $28.68 $17,994 - $22,083
770 New
770 $21,000
Q2 2021

Jul 21, 2021

SELL
$18.78 - $25.15 $75,382 - $100,952
-4,014 Closed
0 $0
Q1 2021

Apr 05, 2021

SELL
$18.21 - $23.2 $40,608 - $51,736
-2,230 Reduced 35.71%
4,014 $75,000
Q4 2020

Jan 20, 2021

BUY
$15.39 - $22.1 $96,095 - $137,992
6,244 New
6,244 $125,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $3.84B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.